+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death



MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death



Journal of Cardiovascular Pharmacology 25(2): 314-323



We studied the electrophysiologic and antifibrillatory properties of MS-551 (1,3-dimethyl-6-((2-[N-hydroxy-ethyl)-3-(4-nitrophenyl) propylamino] ethylamino) 2,4(1H,3H) pyrimidinedione hydrochloride) in a conscious canine model of sudden cardiac death. Three to 5 days after surgically induced myocardial infarction (MI: 2-h occlusion of the left anterior descending coronary artery, LAD), animals were subjected to programmed electrical stimulation (PES) to identify those at risk for sudden cardiac death. MS-551 was administered (2.0, 3.0, or 4 x 2.0 mg/kg intravenously, i.v.). Vehicle-treated animals received 0.9% sodium chloride solution for injection. MS-551 (multiple-dose regimen) increased ventricular effective refractory period (VERP) from 112 +/- 4 to 137 +/- 4 ms (p < 0.05) as compared with vehicle treatment, which did not alter VERP (125 +/- 6 to 121 +/- 5 ms). MS-551 prolonged QTc interval from a predrug value of 293 +/- 8 to 333 +/- 18 ms postdrug. The size of surgically induced MI did not differ among groups: 2.0 mg/kg, 23 +/- 4%; 3.0 mg/kg, 28 +/- 2%; 4 x 2.0 mg/kg, 25 +/- 3%; and vehicle, 28 +/- 3% of the left ventricle. Single bolus administration of MS-551 (2.0 or 3.0 mg/kg i.v.) did not confer significant protection against sudden cardiac death. However, repeated administration of MS-551 protected against sudden cardiac death in 8 of 10 dogs as compared with 2 of 12 in the vehicle-treated group (p < 0.05). The data indicate that a multiple-dose regimen of MS-551 provides protection against ischemia-induced ventricular fibrillation (VF) in the postinfarcted heart. The mechanism by which MS-551 achieves its antifibrillatory effect most likely depends on its ability to prolong VERP of myocardium without altering ventricular conduction velocity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008982744

Download citation: RISBibTeXText

PMID: 7752658

DOI: 10.1097/00005344-199502000-00018


Related references

Tedisamil protects against ventricular fibrillation in a conscious canine model of sudden cardiac death. FASEB Journal 10(3): A33, 1996

Prostacyclin prevents ventricular fibrillation in a canine model of sudden cardiac death. Basic Research in Cardiology 81(1): 40-53, 1986

Tedisamil Attenuates Ventricular Fibrillation in a Conscious Canine Model of Sudden Cardiac Death. Journal of Cardiovascular Pharmacology and Therapeutics 1(4): 313-324, 1996

5-hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death. European Journal Of Pharmacology. 306(1-3): 99-106, 1996

Ventricular fibrillation in a conscious canine model of sudden cardiac death Effects of MS-551, a multiple dose regimen. FASEB Journal 8(4-5): A78, 1994

Study on mechanisms of occurrence of ventricular fibrillation in a new canine model of sudden cardiac death induced by 3 4 diaminopyridine. Japanese Circulation Journal 55(Suppl. A): 417, 1991

Ventricular fibrillation in a conscious canine model of sudden coronary death prevention by chronic amiodarone therapy. American Heart Association Monograph: I-132, 1982

The KATP channel antagonist 5-hydroxydecanoate fails to protect against ventricular fibrillation in a conscious canine model of sudden cardiac death. FASEB Journal 9(3): A605, 1995

Piperazine protects the rat heart against sudden cardiac death from barium chloride-induced ventricular fibrillation. American Journal of Therapeutics 15(2): 119-125, 2008

Implantable cardioverter defibrillator for prevention of sudden cardiac death in patients with ventricular tachycardia and ventricular fibrillation: ICD therapy in sudden cardiac death. Pacing and Clinical Electrophysiology 16(3 Pt 2): 511-518, 1993

Win 54177 4 prevents ventricular fibrillation in a canine model of sudden death. FASEB Journal 2(5): ABSTRACT 7325, 1988

Effect of flecainide acetate on ventricular tachycardia induction and ventricular fibrillation prevention in a conscious canine model of sudden death. Journal of the American College of Cardiology 7(2 Suppl. A): 84A, 1986

Prostacyclin on ventricular fibrillation in a conscious canine model of sudden coronary death. Naunyn-Schmiedeberg's Archives of Pharmacology 321(Suppl.): R54, 1982

Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. American Heart Association Monograph (82): IV-125, 1981

Failure of thromboxane synthetase inhibition to protect the postinfarcted heart against the induction of ventricular tachycardia and ventricular fibrillation in a conscious canine model of sudden coronary death. Pharmacology 37(3): 171-186, 1988